Stock RGC REGENCELL BIOSCIENCE HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Regencell Bioscience Holdings Limited Stock

Equities

RGC

KYG7487R1002

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 03:08:51 2024-04-24 pm EDT 		5-day change 1st Jan Change
5.11 USD -10.35% Intraday chart for Regencell Bioscience Holdings Limited +7.86% -51.33%
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 300M
Net income 2022 -7M Net income 2023 -5M EV / Sales 2022 -
Net cash position 2022 15.65M Net cash position 2023 11.1M EV / Sales 2023 -
P/E ratio 2022
-59.5 x
P/E ratio 2023
-51.1 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 11.24%
More Fundamentals * Assessed data

Chart Regencell Bioscience Holdings Limited

Dynamic Chart

Latest news about Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Regencell Bioscience Holdings Limited Promotes Yat-Pui Au from Senior Vice President to Chief Business Officer CI
Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022 CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period CI
Regencell Bioscience Holdings Limited Announces Resignation of Tien Hsiang Chau as Chief Financial Officer CI
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19 Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial CI
Certain Warrants of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022. CI
Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022. CI
Regencell Bioscience Holdings Limited Appoints William Wing-Yan Lo to Its Board of Directors CI
Regencell Bioscience Holdings Limited Announces Cheung Ming Wong as Independent Director CI
Regencell Bioscience : Forms Joint Venture to Offer COVID-19 Treatment to Select Asia Pacific Countries MT
More news

Analyst Recommendations on Regencell Bioscience Holdings Limited

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial BU
More recommendations

Press releases Regencell Bioscience Holdings Limited

Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K PU
Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K PU
Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K PU
Regencell Bioscience : Changes in Registrant’s Certifying Accountant - Form 6-K PU
Regencell Bioscience : Appointment of Chief Business Officer - Form 6-K PU
More press releases

News in other languages on Regencell Bioscience Holdings Limited

La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días
Regencell Bioscience Holdings Limited : anuncia oferta pública inicial en torno a los u$s 21.900 millones
More news

Quotes and Performance

1 day-11.49%
1 week+53.64%
Current month+26.67%
1 month+62.86%
3 months-36.67%
6 months-66.49%
Current year-45.71%
More quotes

Highs and lows

1 week
4.56
Extreme 4.5553
8.60
1 month
3.16
Extreme 3.16
8.60
Current year
3.16
Extreme 3.16
10.04
1 year
3.16
Extreme 3.16
30.49
3 years
3.16
Extreme 3.16
59.00
5 years
3.16
Extreme 3.16
59.00
10 years
3.16
Extreme 3.16
59.00
More quotes

Managers and Directors - Regencell Bioscience Holdings Limited

Managers TitleAgeSince
Wai Hong Chung COO
 Chief Operating Officer 46 -
Yi-Chung Chao CTO
 Chief Tech/Sci/R&D Officer 59 20-09-30
Yat-Pui Au PRN
 Corporate Officer/Principal - -
Members of the board TitleAgeSince
Wing Yan Lo BRD
 Director/Board Member 63 21-12-12
Yi-Chung Chao CTO
 Chief Tech/Sci/R&D Officer 59 20-09-30
Yat-Gai Au
- -
More insiders

Quotes

Date Price Change Volume
24-04-24 5.11 -10.35% 2 130
24-04-23 5.7 -11.49% 27,364
24-04-22 6.44 +16.04% 3,132
24-04-19 5.55 +6.32% 1,338
24-04-18 5.22 +10.18% 11,218

Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT

More quotes

Company Profile

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REGENCELL BIOSCIENCE HOLDINGS LIMITED Stock Regencell Bioscience Holdings Limited
-45.71% 74.17M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.98% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RGC Stock